High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis

Objectives Non-adherence to therapy is an important cause of suboptimal blood pressure control but few practical tools exist to accurately and routinely detect it. We used a simple urine-based assay to evaluate the prevalence of antihypertensive treatment non-adherence and its impact on blood pressure in a specialist hypertension centre. Methods 208 hypertensive patients (125 new referrals, 66 follow-up patients with inadequate blood pressure control and 17 renal denervation referrals) underwent assessment of antihypertensive drug intake using high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis at the time of clinical appointment. A total of 40 most commonly prescribed antihypertensive medications (or their metabolites) were screened for in spot urine samples. Results Overall, 25% of patients were totally or partially non-adherent to antihypertensive treatment (total non-adherence 10.1%, partial non-adherence 14.9%). The highest prevalence of partial and total non-adherence was among follow-up patients with inadequate blood pressure control (28.8%) and those referred for consideration of renal denervation (23.5%), respectively. There was a linear relationship between blood pressure and the numerical difference in detected/prescribed antihypertensive medications—every unit increase in this difference was associated with 3.0 (1.1) mm Hg, 3.1 (0.7) mm Hg and 1.9 (0.7) mm Hg increase in adjusted clinic systolic blood pressure, clinic diastolic blood pressure (DBP) and 24 h mean daytime DBP (p=0.0051, p=8.62×10−6, p=0.0057), respectively. Conclusions Non-adherence to blood pressure lowering therapy is common, particularly in patients with suboptimal blood pressure control and those referred for renal denervation. HP LC-MS/MS urine analysis could be used to exclude non-adherence and better stratify further investigations and intervention.

[1]  R. Fitzgerald,et al.  Broad spectrum drug identification directly from urine, using liquid chromatography-tandem mass spectrometry. , 1999, Clinical chemistry.

[2]  W. Grzeszczak,et al.  [The evaluation of hypertensive patients' adherence to the pharmacological treatment of hypertension]. , 1999, Wiadomosci lekarskie.

[3]  R. Nuesch,et al.  Relation between insufficient response to antihypertensive treatment and poor compliance with treatment: a prospective case-control study , 2001, British medical journal.

[4]  J. S. Chatterjee,et al.  From compliance to concordance in diabetes , 2006, Journal of Medical Ethics.

[5]  N. Rodondi,et al.  Impact of electronic monitoring of drug adherence on blood pressure control in primary care: a cluster 12-month randomised controlled study. , 2008, European journal of internal medicine.

[6]  John Urquhart,et al.  Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories , 2008, BMJ : British Medical Journal.

[7]  M. Mazzarino,et al.  A screening method for the simultaneous detection of glucocorticoids, diuretics, stimulants, anti-oestrogens, beta-adrenergic drugs and anabolic steroids in human urine by LC-ESI-MS/MS , 2008, Analytical and bioanalytical chemistry.

[8]  A. Chobanian.  Impact of nonadherence to antihypertensive therapy. , 2009, Circulation.

[9]  Krzysztof Bartus,et al.  Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study , 2009, The Lancet.

[10]  J. Danaceau,et al.  Simultaneous extraction and screening of diuretics, beta-blockers, selected stimulants and steroids in human urine by HPLC-MS/MS and UPLC-MS/MS. , 2009, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[11]  Alessandro Filippi,et al.  Adherence to Antihypertensive Medications and Cardiovascular Morbidity Among Newly Diagnosed Hypertensive Patients , 2009, Circulation.

[12]  H. Krum,et al.  Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial , 2010, The Lancet.

[13]  John F. Steiner,et al.  Rethinking Adherence , 2012, Annals of Internal Medicine.

[14]  G. Parati,et al.  ESH position paper: renal denervation - an interventional therapy of resistant hypertension. , 2012, Journal of hypertension.

[15]  W. Elliott.  Better compliance to antihypertensive medications reduces cardiovascular risk , 2012 .

[16]  A. Kessels,et al.  Electronic monitoring of adherence, treatment of hypertension, and blood pressure control. , 2012, American journal of hypertension.

[17]  J. Staessen,et al.  Renal Denervation: Ultima Ratio or Standard in Treatment-Resistant Hypertension , 2012, Hypertension.

[18]  R. Cote,et al.  Adherence to antihypertensive agents after ischemic stroke and risk of cardiovascular outcomes , 2012, Neurology.

[19]  Deepak L. Bhatt,et al.  Renal Sympathetic Denervation Therapy for Resistant Hypertension: A Contemporary Synopsis and Future Implications , 2013, Circulation. Cardiovascular interventions.

[20]  R. Burrow,et al.  Heart , 2013, Feline Soft Tissue and General Surgery.

[21]  R. Carey.  Resistant hypertension. , 2013, Hypertension.

[22]  B. Williams,et al.  Expert consensus document from the European Society of Cardiology on catheter-based renal denervation. , 2013, European heart journal.

[23]  杜昕,et al.  Resistant hypertension , 2013 .

[24]  S. Toennes,et al.  Resistant hypertension? Assessment of adherence by toxicological urine analysis , 2013, Journal of hypertension.